This Collection invites original research articles on phase contrast imaging, looking at the latest technological developments and the use of this technique in original applications. Phase contrast ...
Techniques that exploit the phase of X-rays, not just their absorption, have the potential to transform X-ray imaging in hospitals, reports Jude Dineley Improved imaging Marian Willner from the ...
GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 ...
Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
Medical Device Network on MSN
First patient dosed in GE HealthCare’s Phase II/III LUMINA clinical trial
Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings.
MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating ...
MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results